Jared Kaltwasser

Patients with sickle cell disease who do not receive treatment can die from the disease, but diagnostic resources are scarce in some parts of the world where the disease is most prevalent. A new smartphone-based method could change that.

Patients with relapsed/refractory T-cell lymphoblastic leukemia face poor outcomes, and are generally treated by salvage therapy followed by allogeneic hematopoietic stem cell transplant. A new study suggests an optimal option for salvage therapy.

A subset of patients taking ibrutinib as a therapy for chronic lymphocytic leukemia (CLL) will require dose modifications. A new study attempts to evaluate the impacts of such changes, though the authors find many questions remain unsolved.

A new large randomized trial indicates induction therapy including lenalidomide is optimal in patients with multiple myeloma who are transplant-eligible. Maintenance with lenalidomide was preferable to observation alone following transplant.

Patients with multiple myeloma (MM) face higher risks of certain metabolic syndromes, but new research suggests those risks exist even in patients with smoldering MM.

Accurate risk assessment is a highly technical process for patients with acute myeloid leukemia (AML). A new tool could help make such assessments available even when patients can’t get to a specialty care center.

A new study finds a significant proportion of patients with multiple myeloma (MM) who receive lenalidomide maintenance will see their disease response deepen and many will achieve minimal residual disease negativity.

Peripheral T-cell lymphoma (PTCL) has been a challenging nemesis for scientists, in large part because it is a widely heterogeneous disease. However, new research into biomarkers for the cancer may lead to better therapies soon.

New therapies for autoimmune conditions like rheumatoid arthritis (RA) highlight the potential of metabolic targets. A recent study highlights some of the most promising targets.

As investigators have learned more about how to diagnose and categorize smoldering multiple myeloma (SMM), a new review article argues there’s insufficient data to evolve beyond a close observation approach.

A new review article outlining research into multiple myeloma with central nervous system (CNS) involvement explains the many reasons it is difficult to diagnose and treat the disease.

Clinicians use the presence or absence of minimal residual disease as a metric by which to judge the efficacy of therapy in patients with hematological malignancies. A new review article interrogates whether that approach aligns with patient-centered outcomes.

New advances in therapy have led to better long-term survival rates in patients with hematologic malignancies, but there are some caveats to the good news.

Despite some clues, scientists don’t yet understand which patients with psoriasis are likely to eventually develop psoriatic arthritis; solving that riddle could have major impacts on patient care.

A new study that looks at the long-term effects of dimethyl fumarate finds the therapy is safe and effective in patients with relapsing-remitting multiple sclerosis who have taken the therapy for approximately a decade.

Psoriatic arthritis and psoriasis both place a significant economic burden on patients, but a new analysis shows the burden on people with the former is significantly higher.

The bruton tyrosine kinase inhibitor zanubrutinib was shown to generate high response rates in a new study of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

A new report shows just how much disease modifying therapies (DMTs) have changed the economic landscape of treating multiple sclerosis.

Five metabolic inhibitors appear to have strong antiproliferative effects on acute myeloid leukemia (AML), according to a new study.

Identifying the particular genes at play in multiple sclerosis (MS) could lead to a better understanding of the disease, and possibly better therapies for it. A new paper proposes network representation learning as the best method to identify those genes.

Some oncologists refrain from prescribing checkpoint immunotherapy in patients with Kaposi sarcoma who also have psoriasis or other skin conditions. A new case report says the therapy can be successfully completed while still controlling the skin condition.

It’s rare for a patient to be diagnosed with both acute myeloid leukemia and multiple myeloma at the same time, but a new case study suggests there are options to treat both diseases at the same time in such cases.

Patients who are treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia are at a higher risk of a secondary malignancy. A new case study suggest the list of potential secondary malignancies should include lymphoplasmacytic lymphoma.

A new study based on interviews with families and patients undergoing chronic transfusion therapy for sickle cell disease finds that the therapy affects the families in ways that extend beyond health.

A new analysis of patients with early multiple sclerosis (MS) suggests they universally carry antibodies for Epstein-Barr virus, a virus increasingly thought to be linked to MS.

New data suggests white patients who are deficient in vitamin D have lower rates of survival when diagnosed with multiple myeloma. The phenomenon was not seen, however, in African American patients.

A new report on 3 rare cases of patients with myeloproliferative neoplasms who developed T-cell malignancies sheds light on red flags clinicians should look for.

A new large-scale study of patients with myeloproliferative neoplasm finds they are at twice the risk of mortality from respiratory disease.

New research suggests disparities in incidence and survival rates in multiple myeloma may have a lot to do with healthcare quality and access to care.

Clinicians treating patients with multiple myeloma have a number of factors to consider as they treat patients in an era of high-risk COVID-19 infection.